{"id":"https://openalex.org/W4248926061","doi":"https://doi.org/10.1055/s-0033-1357211","title":"Development of a Subcutaneous Formulation for Trastuzumab \u2013 Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen","display_name":"Development of a Subcutaneous Formulation for Trastuzumab \u2013 Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen","alternate_titles":[],"publication_year":2013,"publication_date":"2013-10-10","ids":{"openalex":"https://openalex.org/W4248926061","doi":"https://doi.org/10.1055/s-0033-1357211"},"language":"en","primary_location":{"id":"doi:10.1055/s-0033-1357211","doi":"https://doi.org/10.1055/s-0033-1357211","is_oa":false,"landing_page_url":"https://doi.org/10.1055/s-0033-1357211","pdf_url":null,"source":{"id":"https://openalex.org/S4210226141","display_name":"Drug Research","issn_l":"2194-9379","issn":["2194-9379","2194-9387"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","medline","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4248926061"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008248783","display_name":"Beate Bittner","orcid":"https://orcid.org/0000-0002-8126-116X","observed_orcids":["https://orcid.org/0000-0002-8126-116X"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"B. Bittner","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland","F. Hoffmann-La Roche Ltd., Pharma Medicines Global Product Strategy, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]},{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd., Pharma Medicines Global Product Strategy, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048684851","display_name":"W. Richter","orcid":"https://orcid.org/0000-0002-8094-8605","observed_orcids":["https://orcid.org/0000-0002-8094-8605"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"W. Richter","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd., Nonclinical Safety, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd., Nonclinical Safety, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042799528","display_name":"Florence Hourcade\u2010Potelleret","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"F. Hourcade-Potelleret","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd., Clinical Modeling & Simulation, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd., Clinical Modeling & Simulation, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066034815","display_name":"Christine McIntyre","orcid":"https://orcid.org/0009-0000-6504-570X","observed_orcids":["https://orcid.org/0009-0000-6504-570X"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"C. McIntyre","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015755137","display_name":"F. Herting","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"F. Herting","raw_affiliation_strings":["Roche Diagnostics GmbH, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roche Diagnostics GmbH, Penzberg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027591873","display_name":"Monica L. Zepeda","orcid":"https://orcid.org/0000-0002-4127-007X","observed_orcids":["https://orcid.org/0000-0002-4127-007X"]},"institutions":[{"id":"https://openalex.org/I4210088034","display_name":"Halozyme Therapeutics (United States)","ror":"https://ror.org/001x5ea44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088034"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Zepeda","raw_affiliation_strings":["Halozyme Therapeutics Inc., San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Halozyme Therapeutics Inc., San Diego, CA, USA","institution_ids":["https://openalex.org/I4210088034"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053315132","display_name":"Johannes Schmidt","orcid":"https://orcid.org/0000-0002-5340-8611","observed_orcids":["https://orcid.org/0000-0002-5340-8611"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Schmidt","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd., Pharma Medicines Global Product Strategy, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd., Pharma Medicines Global Product Strategy, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.8168,"has_fulltext":false,"cited_by_count":38,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.91049914,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"63","issue":"11","first_page":"602","last_page":"602"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.4957999885082245,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.4957999885082245,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.2084999978542328,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.16750000417232513,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":1.0},{"id":"https://openalex.org/keywords/subcutaneous-formulation","display_name":"subcutaneous formulation","score":0.9929999709129333},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.7020000219345093},{"id":"https://openalex.org/keywords/nonclinical-pharmacology","display_name":"nonclinical pharmacology","score":0.48899999260902405},{"id":"https://openalex.org/keywords/clinical-pharmacology","display_name":"clinical pharmacology","score":0.6320000290870667}],"concepts":[{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.8846954107284546},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.7542386054992676},{"id":"https://openalex.org/C174348530","wikidata":"https://www.wikidata.org/wiki/Q188635","display_name":"Bridging (networking)","level":2,"score":0.7355955839157104},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7102649211883545},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5928505063056946},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3837854266166687},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2858465313911438},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.09665283560752869},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.09453386068344116},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.07237657904624939},{"id":"https://openalex.org/C31258907","wikidata":"https://www.wikidata.org/wiki/Q1301371","display_name":"Computer network","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1055/s-0033-1357211","doi":"https://doi.org/10.1055/s-0033-1357211","is_oa":false,"landing_page_url":"https://doi.org/10.1055/s-0033-1357211","pdf_url":null,"source":{"id":"https://openalex.org/S4210226141","display_name":"Drug Research","issn_l":"2194-9379","issn":["2194-9379","2194-9387"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","medline","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1906683030","https://openalex.org/W2892750202","https://openalex.org/W2107103026","https://openalex.org/W2047652278","https://openalex.org/W1648925388","https://openalex.org/W3130246562","https://openalex.org/W2917182113","https://openalex.org/W2269901519","https://openalex.org/W4319724237","https://openalex.org/W4206382825"],"abstract_inverted_index":{"Correction":[0],"to:":[1],"Development":[2,28],"of":[3,29],"a":[4,30],"Subcutaneous":[5,31],"Formulation":[6,32],"for":[7,33,89],"Trastuzumab":[8,34],"\u2013":[9,35],"Nonclinical":[10,36],"and":[11,37],"Clinical":[12,38],"Bridging":[13,39],"Approach":[14,40],"to":[15,41,72],"the":[16,42,83,87,90,94],"Approved":[17,43],"Intravenous":[18,44],"Dosing":[19,45],"Regimen":[20,46],"Arzneimittelforschung":[21,63],"2012;":[22,64],"62(09):":[23],"401-409":[24],"DOI:":[25,67],"10.1055/s-0032-1321831":[26,68],"Erratum":[27],"B.":[47],"Bittner,":[48],"W.":[49],"F.":[50,52,56],"Richter,":[51],"Hourcade-Potelleret,":[53],"C.":[54],"McIntyre,":[55],"Herting,":[57],"M.":[58],"L.":[59],"Zepeda,":[60],"J.":[61],"Schmidt":[62],"62:":[65],"401\u2013409":[66],"The":[69],"references":[70],"referring":[71],"other":[73],"sections":[74],"like":[75],"\u201cSection":[76],"6.4\u201c":[77],"are":[78],"no":[79],"longer":[80],"valid":[81],"as":[82],"new":[84],"formatting":[85],"removed":[86],"numbers":[88],"different":[91],"paragraphs":[92],"in":[93],"article.":[95]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4248926061","counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":12},{"year":2013,"cited_by_count":4}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2022-05-12T00:00:00"}
